FDA approves 1st biosimilar to treat cancer

The Food and Drug Administration on Thursday approved Amgen and Allergan's biosimilar version of Roche's cancer drug Avastin.

Mvasi is approved to treat patients with certain colorectal, lung, brain, kidney and cervical cancers in combination with other therapies.

Mvasi is the first biosimilar approved by the FDA to treat cancer and represents one of four oncology bisomilars Amgen and Allergan are co-developing.

More articles on supply chain:

Teva to sell contraceptive device business for $1.1B, divest remaining women's health assets
FDA reapproves leukemia drug 7 years after pulled from market
Supply chain inefficiencies leave $23B in potential savings on the table for hospitals

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars